CR3022-derived Anti-SARS-CoV2 RBD mAbs, human & mouse isotypes

Anti-Spike RBD antibody - Human & mouse isotypes

ABOUT

Anti-SARS-CoV-2 & SARS-CoV Spike recombinant antibody

Antibody description

InvivoGen provides a family of Anti-Spike RBD CR3022-derived monoclonal antibodies (mAbs) in multiple human and mouse isotypes. These mAbs feature:

  • the variable region of the CR3022 human mAb that specifically targets the Spike receptor-binding domain (RBD) [1]
  • a constant region that mediates different effector functions depending on the isotype (human IgG1, hIgG1NQ, hIgA1, or hIgM, and mouse IgG2a or mIgG1e3 ) (See Table)

The Anti-Spike RBD clone CR3022 is a SARS-CoV neutralizing antibody that was obtained from the screening of an antibody-phage library and converted to a human IgG1 format [1]. SARS-CoV and SARS-CoV-2 (2019-nCoV) RBD share a highly conserved epitope (86% shared identity) that is recognized by CR3022 [2, 3]. To date, the neutralization potency of CR3022 for SARS-CoV-2 is still unclear [3, 4]. Indeed, CR3022 does not interfere with the ACE2 binding motif [2-4].

 

More details More details

 

Applications

  • Detection of the presence of viral particles in culture supernatant or in serum (ELISA)
  • Control of antibody-mediated effector functions (i.e. absence, increase or decrease in ADCC, ADCP, or CDC) (See Table)

Quality control

  • Isotype confirmed by ELISA
  • Functionality validated by ELISA using a coated Spike-RBD-His fusion peptide

 

Our CR3022 variants have been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography.

All the SARS-CoV-2-related antibodies are in stock now and can be shipped out immediately.

 

Learn more on SARS-CoV-2 Read our reviews discussing SARS-CoV-2

 

References

1. Ter Muelen J. et al., 2006. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLos Med. 3(7):e237.
2. Yuan M. et al., 2020. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. DOI: 10.1126/science.abb7269.
3. Tian X. et al., 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes & Infections. 9(1):382-385.
4. Huo J. et al., 2020. Neutralization of SARS-CoV-2 by destruction of the prefusion Spike. bioRxiv. DOI:10.1101/2020.05.05.079202.

All products are for internal research use only, and not for human or veterinary use.

Simplified schematic of CR3022- and ACE2-binding sites in Spike RBD
Simplified schematic of CR3022- and ACE2-binding sites in Spike RBD

Available upon request

SPECIFICATIONS

Specifications

Applications

Detection of the presence of viral particles in culture supernatant or in serum (ELISA) Control of antibody-mediated effector functions (i.e. absence, increase or decrease in ADCC, ADCP, or CDC) (See Table)

Species
Human
Isotype
hIgG1
Source
CHO cells
Formulation buffer

Sodium phosphate buffer with glycine, saccharose, and stabilizing agent

Preservative
Azide-free
Appearance (form)
Lyophilized pellet
Appearance (color)
White
Tested applications

Detection of the presence of viral particles in culture supernatant or in serum (ELISA), Control of antibody-mediated effector functions (i.e. absence, increase or decrease in ADCC, ADCP, or CDC) (See Table)

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-Spike-RBD-hIgG1 (CR3022)
  • Cat code: 
    srbd-mab1-3
  • Quantity: 
    3 x 100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Previous studies during the SARS-CoV outbreak have identified Spike-specific neutralizing antibodies in the serum of convalescent patients, and have shown that most of them target the ACE2 receptor-binding domain (RBD) [1]. Thus, Spike RBD is a privileged candidate for vaccination and treatment strategies in the context of COVID-19.
 
One strategy is to study the potential cross-reactivity of SARS-CoV neutralizing antibodies with the SARS-CoV-2.
The anti-Spike RBD clone CR3022 is a SARS-CoV neutralizing antibody that was obtained from the screening of an antibody-phage library and converted to a human IgG1 format [2]. SARS-CoV-2 and SARS-CoV Spike RBD share 73% identity [3]. Modeling and in vitro studies have shown that CR3022 is also binding to SARS-CoV-2 RBD [4]. This cross-reactivity is explained by the 86% shared amino acid identity between the CR3022 epitopes from the two viruses [4]. Importantly, CR3022 does not interfere with the ACE2 binding motif [2-5]. Thus, CR3022 could be used alone or in combination with other antibodies or soluble ACE2 to maximize the neutralization of SARS-CoV-2 (Wuhan-Hu-1, D614) and mutant isolates [6].
 
Structural studies have led to a binding model where:
  • the CR3022 epitope in RBD does not overlap with the ACE2 receptor binding motif [2-5]
  • the CR3022 epitopes in SARS-CoV and SARS-CoV-2 RBD share 24 residues out of 28 (86% identity in amino acids) [4]
  • Spike trimers stochastically exhibit their RBD in a “down” or “up” state [7, 8]
  • the CR3022 antibody only accesses its epitope when at least two RBDs are in the “up” conformation and slightly-rotated [4, 5]
  • CR3022 does not sterically prevent ACE2 binding to RBD [4, 5]
 
To this date, there are discrepancies among studies addressing the CR3022 neutralization activity and underlying mechanisms.
Yuan et al. used a microneutralization assay to show that CR3022 can neutralize SARS-CoV, but not SARS-CoV-2 [4]. On the contrary, Huo et al, showed that CR3022 does neutralize SARS-CoV-2, and their experimental data suggest that neutralization occurs by the destruction of the Spike protein in its prefusion conformation [5].
 

References

1. Jiang S. et al. 2020. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 41 (5):355-359.
2. Ter Muelen J.et al., 2006. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLos Med. 3(7):e237.
3. Tian X. et al., 2020. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes & Infections. 9(1):382-385.
4. Yuan M. et al., 2020. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science. DOI: 10.1126/science.abb7269.
5. Huo J. et al., 2020. Neutralization of SARS-CoV-2 by destruction of the prefusion Spike. bioRxiv. DOI:10.1101/2020.05.05.079202.
6. Korber B. et al., 2020. Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2. bioRxiv. DOI:10.1101/2020.04.29.069054.
7. Walls A.C. et al., 2020. Structure, function, and antigenicity of the SARS-CoV-2 Spike glycoprotein. Cell. 181(2):281-292.e6.
8. Wrapp D. et al., 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 367:1260-1263.

DOCUMENTS

Documents

Anti-Spike-RBD-hIgG1 (CR3022)

Technical Data Sheet

Validation Data Sheet

Safety Data Sheet

View document

Certificate of analysis

Need a CoA ?

Contact us

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?